358 related articles for article (PubMed ID: 36152266)
21. Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis.
Bloom JL; Langford CA; Wechsler ME
Rheum Dis Clin North Am; 2023 Aug; 49(3):563-584. PubMed ID: 37331733
[TBL] [Abstract][Full Text] [Related]
22. [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].
Hellmich B; Holle J; Moosig F
Z Rheumatol; 2022 May; 81(4):286-299. PubMed ID: 35075511
[TBL] [Abstract][Full Text] [Related]
23. Case Report: Middle lobe syndrome: a rare presentation in eosinophilic granulomatosis with polyangiitis.
Maranini B; Guzzinati I; Casoni GL; Ballotta M; Lo Monaco A; Govoni M
Front Immunol; 2023; 14():1222431. PubMed ID: 37638004
[TBL] [Abstract][Full Text] [Related]
24. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
26. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
27. [Vasculitides and eosinophilic pulmonary diseases].
Kroegel C; Foerster M; Quickert S; Slevogt H; Neumann T
Z Rheumatol; 2018 Dec; 77(10):907-922. PubMed ID: 30367242
[TBL] [Abstract][Full Text] [Related]
28. Mepolizumab: Therapeutic strategy for a pediatric patient with eosinophilic granulomatosis with polyangiitis.
Ozola L; Aleksejeva E; Stoldere D; Dāvidsone Z; Šantere R; Grantiņa I; Cīrule I; Krams A
Pediatr Pulmonol; 2023 Mar; 58(3):973-979. PubMed ID: 36404638
[TBL] [Abstract][Full Text] [Related]
29. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
30. An update on dıagnosıs and treatment of ANCA assocıated renal vasculıtıs.
Turkmen K; Ozer H; Tesar V
Int Urol Nephrol; 2023 Nov; 55(11):2817-2827. PubMed ID: 37010734
[TBL] [Abstract][Full Text] [Related]
31. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
32. ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics.
Piga MA; Fraticelli P; Antonicelli L; Garritani MS; Ghirelli G; Martini M; Di Vincenzo A; Danieli MG; Moroncini G; Bilò MB
Front Immunol; 2023; 14():1325299. PubMed ID: 38090592
[TBL] [Abstract][Full Text] [Related]
33. Eosinophilic granulomatosis polyangiitis (EGPA) complicated with periaortitis, precipitating role of dupilumab? A case report a review of the literature.
Kai M; Vion PA; Boussouar S; Cacoub P; Saadoun D; Le Joncour A
RMD Open; 2023 Sep; 9(3):. PubMed ID: 37673442
[TBL] [Abstract][Full Text] [Related]
34. The Reclassification of Patients With Previously Diagnosed Eosinophilic Granulomatosis With Polyangiitis Based on the 2022 ACR/EULAR Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Pyo JY; Ahn SS; Song JJ; Park YB; Lee SW
J Rheumatol; 2023 Feb; 50(2):213-218. PubMed ID: 36109070
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases.
Sreih AG; Annapureddy N; Springer J; Casey G; Byram K; Cruz A; Estephan M; Frangiosa V; George MD; Liu M; Parker A; Sangani S; Sharim R; Merkel PA;
Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1368-1374. PubMed ID: 27804171
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous manifestations of antineutrophil cytoplasmic antibody-associated vasculitis (AAV): a concise review with emphasis on clinical and histopathologic correlation.
Gibson LE
Int J Dermatol; 2022 Dec; 61(12):1442-1451. PubMed ID: 35599359
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil extracellular traps formation in patients with eosinophilic granulomatosis with polyangiitis: association with eosinophilic inflammation.
Natorska J; Ząbczyk M; Siudut J; Krawiec P; Mastalerz L; Undas A
Clin Exp Rheumatol; 2017; 35 Suppl 103(1):27-32. PubMed ID: 28229830
[TBL] [Abstract][Full Text] [Related]
38. Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.
Tsioulos G; Kounatidis D; Vallianou NG; Koufopoulos N; Katsimbri P; Antoniadou A
Am J Med Sci; 2023 Jan; 365(1):93-98. PubMed ID: 35970248
[TBL] [Abstract][Full Text] [Related]
39. ANCA-negative ANCA-associated vasculitis: pitfalls of the 'vasculitis screen'.
Cooke H; Wells M; Miller K; Medford ARL; Patel S
Clin Med (Lond); 2023 Nov; 23(6):630-632. PubMed ID: 38065599
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis.
Hazebroek MR; Kemna MJ; Schalla S; Sanders-van Wijk S; Gerretsen SC; Dennert R; Merken J; Kuznetsova T; Staessen JA; Brunner-La Rocca HP; van Paassen P; Cohen Tervaert JW; Heymans S
Int J Cardiol; 2015 Nov; 199():170-9. PubMed ID: 26209947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
